SNV1521 clinical trials
SNV1521 is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Belgium, Canada and Australia registers. 2 are recruiting patients now. All registered phases are Phase 1. The lead sponsor is ParVation Therapeutics, Inc. The most-studied condition is Advanced Solid Tumor.
Patient leaflets for SNV1521
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of SNV1521
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
SNV1521 in Participants With Advanced Solid Tumors
NCT06220864 · Advanced Solid Tumor
|
Phase 1 | Recruiting | ParVation Therapeutics, Inc | USA, France, Spain, Italy, Belgium, Canada, Australia |
|
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
NCT07756281 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Acinar Carcinoma
|
Phase 1 | Recruiting | ParVation Therapeutics, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with SNV1521
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| ParVation Therapeutics, Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Belgium | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about SNV1521 trials
How many clinical trials are testing SNV1521?
2 current trials in our USA, France, Spain, Italy, Belgium, Canada and Australia registers name SNV1521 as a drug or biological intervention, as of the registry sync on 28 October 2026. Completed and withdrawn studies are not counted.
Are SNV1521 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors SNV1521 clinical trials?
The lead sponsor is ParVation Therapeutics, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SNV1521 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SNV1521 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SNV1521 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.